Table 1 Baseline patient descriptives and clinical risk factors for severe COVID-19 infection
BA.1 (n = 70) | BA.2 (n = 15) | P value | |
|---|---|---|---|
Age, mean in years (standard deviation, SD) | 58.5 (19.8) | 61.0 (16.2) | 0.613 |
Female | 37 (52.9%) | 4 (26.7%) | 0.089 |
Received 2 or more doses of COVID-19 vaccines | 56 (80.0%) | 13 (86.7%) | 0.726 |
Prior COVID-19 infection | 0 (0%) | 0 (0%) | N/A |
Immunocompromised | 47 (67.1%) | 9 (60.0%) | 0.765 |
Solid organ transplant | 20 (28.6%) | 6 (40.0%) | 0.376 |
Haematopoietic stem cell transplant | 2 (2.9%) | 0 (0%) | > 0.999 |
Haematologic malignancy | 7 (10.0%) | 0 (0%) | 0.344 |
Solid tumour cancer | 6 (8.6%) | 0 (0%) | 0.585 |
Primary immunodeficiency | 1 (1.4%) | 0 (0%) | > 0.999 |
HIV/AIDS | 0 (0%) | 0 (0%) | N/A |
High dose steroids (≥ 20 mg prednisone equivalent > 2 weeks) | 10 (14.3%) | 3 (20.0%) | 0.693 |
Chemotherapy | 8 (11.4%) | 0 (0%) | 0.340 |
Biologic for rheumatic diseases | 8 (11.4%) | 1 (6.7%) | > 0.999 |
Conventional DMARD for rheumatic diseases | 19 (27.1%) | 6 (40.0%) | 0.357 |
Number of risk factors for progression to severe disease, mean (SD) | 1.9 (1.7) | 3.1 (2.0) | 0.052 |
Obesity | 13 (18.6%) | 1 (6.7%) | 0.447 |
Diabetes mellitus | 21 (30.0%) | 6 (40.0%) | 0.544 |
Hypertension | 31 (44.3%) | 10 (66.7%) | 0.157 |
Coronary artery disease | 11 (15.7%) | 7 (46.7%) | 0.014 |
Congestive heart failure | 5 (7.1%) | 6 (40.0%) | 0.003 |
Chronic respiratory disease | 17 (24.3%) | 3 (20.0%) | > 0.999 |
Cerebral palsy | 0 (0%) | 0 (0%) | N/A |
Intellectual disability | 5 (7.1%) | 1 (6.7%) | > 0.999 |
Sickle cell disease | 0 (0%) | 0 (0%) | N/A |
Chronic kidney disease, eGFR < 60 mL/min | 24 (34.3%) | 8 (53.3%) | 0.240 |
Liver disease | 6 (8.6%) | 4 (26.7%) | 0.070 |
Pregnancy | 2 (2.9%) | 0 (0%) | > 0.999 |
Symptoms, days before sotrovimab. Mean (SD) | 3.9 (1.6) | 3.6 (1.5) | 0.416 |